Program: IgY-112
Stage: Discovery

IgY for Celiac disease contain polyclonal IgY antibodies that block the interaction of hypersensitive or excessive mucosal immune responses with microbial and protein components that are associated with celiac disease pathogenesis. We are researching the effectiveness of an oral therapeutic using a capsule-based format to deliver the antibodies directly to the small intestine where the inflammation takes place for better management of the disease.

Please contact us to learn more about Celiac disease IgY or to explore partnership opportunities.